Combining BRAFV600E Inhibitor with TRAIL to Treat Colon Cancer
Author Information
Author(s): Oikonomou Eftychia, Koc Michal, Sourkova Vladimira, Andera Ladislav, Pintzas Alexander
Primary Institution: Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
Hypothesis
Can the selective BRAFV600E inhibitor PLX4720 be effectively combined with TRAIL to overcome resistance in colon cancer cells?
Conclusion
The study found that combining PLX4720 with TRAIL can enhance apoptosis in BRAFV600E mutant colon cancer cells, suggesting a potential therapeutic strategy.
Supporting Evidence
- PLX4720 alone was ineffective in inducing apoptosis in certain colon cancer cell lines.
- TRAIL was shown to enhance the apoptotic effects when combined with PLX4720.
- The presence of PIK3CA mutations was identified as a factor contributing to resistance.
Takeaway
This study shows that using a special cancer drug with another drug can help kill cancer cells that are usually hard to treat.
Methodology
The study used various colon cancer cell lines to test the effects of PLX4720 and TRAIL on cell death and signaling pathways.
Limitations
The study primarily focused on in vitro models, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website